Nevirapine plasma concentrations are associated with virologic response and hepatotoxicity in Chinese patients with HIV infection

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Wang, Jia ^a,b   Kou, Huijuan ^a   Fu, Qiang ^a   Han, Yang ^a   Qiu, Zhifeng ^a   Zuo, Lingyan ^a   Li, Yanling ^a   Zhu, Zhu ^a   Ye, Min ^a   Ma, Qing ^c,d   Li, Taisheng ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b Jishuitan Orthopaedic College of Tsinghua University   (China)

^c UNIVERSITY AT BUFFALO   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE; VIRUS RNA;

ADULT; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CHINESE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG TREATMENT FAILURE; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; VIROLOGY; VIRUS LOAD; ASIAN; BLOOD; CHINA; CLINICAL TRIAL (TOPIC); DEMOGRAPHY; DRUG EFFECT; HEPATITIS C VIRUS; IMMUNOLOGY; LIVER; MIDDLE AGED; PATHOLOGY; RISK FACTOR; STATISTICAL MODEL;

HEPATITIS C VIRUS;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CD4 LYMPHOCYTE COUNT; CHINA; CLINICAL TRIALS AS TOPIC; DEMOGRAPHY; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; LINEAR MODELS; LIVER; MALE; MIDDLE AGED; NEVIRAPINE; RISK FACTORS; RNA, VIRAL; ROC CURVE;

EID: 80055106975     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026739     Document Type: Article

References (24)

1. Li T, Dai Y, Kuang J, Jiang J, Han Y, et al. (2008) Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort. PLoS One 3: e3918.
2. de Vries-Sluijs TE, Dieleman JP, Arts D, Huitema AD, Beijnen JH, et al. (2003) Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet 42: 599-605.
3. Duong M, Buisson M, Peytavin G, Kohli E, Piroth L, et al. (2005) Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIV-infected patients who switched from protease inhibitors. Ann Pharmacother 39: 603-609.
4. Veldkamp AI, Weverling GJ, Lange JM, Montaner JS, Reiss P, et al. (2001) High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 15: 1089-1095.
5. Dailly E, Billaud E, Reliquet V, Breurec S, Perre P, et al. (2004) No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors. Eur J Clin Pharmacol 60: 343-348.
6. Gonzalez de Requena D, Nunez M, Jimenez-Nacher I, Soriano V, (2002) Liver toxicity caused by nevirapine. AIDS 16: 290-291.
7. Kappelhoff BS, van Leth F, Robinson PA, MacGregor TR, Baraldi E, et al. (2005) Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir Ther 10: 489-498.
8. Nunez M, Gonzalez-Requena D, Gonzalez-Lahoz J, Soriano V, (2003) Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients. AIDS Res Hum Retroviruses 19: 187-188.
9. Molto J, Blanco A, Miranda C, Miranda J, Puig J, et al. (2007) Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice. Br J Clin Pharmacol 63: 715-721.
10. Haas DW, (2005) Pharmacogenomics and HIV therapeutics. J Infect Dis 191: 1397-1400.
11. Kappelhoff BS, van Leth F, MacGregor TR, Lange J, Beijnen JH, et al. (2005) Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir Ther 10: 145-155.
12. Ma Q, Okusanya OO, Smith PF, Dicenzo R, Slish JC, et al. (2005) Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors. Expert Opin Drug Metab Toxicol 1: 473-485.
13. Stohr W, Back D, Dunn D, Sabin C, Winston A, et al. (2008) Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther 13: 675-685.
14. Gonzalez de Requena D, Bonora S, Garazzino S, Sciandra M, D'Avolio A, et al. (2005) Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting. Antimicrob Agents Chemother 49: 3966-3969.
15. De Requena DG, Jimenez-Nacher I, Soriano V, (2005) Changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations. AIDS Res Hum Retroviruses 21: 555-559.
16. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD, (2002) Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 35: 182-189.
17. van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, et al. (2004) Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 363: 1253-1263.
18. Baylor MS, Johann-Liang R, (2004) Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr 35: 538-539.
19. Fuping G, Wei L, Yang H, Zhifeng Q, Lingyan Z, et al. (2010) Impact of hepatitis C virus coinfection on HAART in HIV-infected individuals: multicentric observation cohort. J Acquir Immune Defic Syndr 54: 137-142.
20. Labarga P, Soriano V, Vispo ME, Pinilla J, Martin-Carbonero L, et al. (2007) Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 196: 670-676.
21. Stone SF, Lee S, Keane NM, Price P, French MA, (2002) Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients. J Infect Dis 186: 1498-1502.
22. van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Wit FW, et al. (2000) The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS 14: F77-82.
23. Huang TM, Yang B, Sha YF, Duan GL, (2005) Comparative bioequivalence of domestic and imported nevirapine tablets in human. Chin J New Drugs Clin Rem 24: 505-508.
24. Donnerer J, Haas BJ, Kessler HH, (2008) Single-measurement therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, lamivudine, efavirenz, nevirapine, lopinavir and nelfinavir. Pharmacology 82: 287-292.